A study said that a mixture of antibodies produced by AstraZeneca retained neutralizing activity against the mutant. AstraZeneca Inc. said Tuesday it is working with Oxford University to produce a vaccine for the mutated Omicron strain of the Corona virus, joining other vaccine makers looking to produce an anti-mutated vaccine. “In cooperation with the University of Oxford, we have taken initial steps towards producing a vaccine for the Omicron mutant in case it is needed,” a company spokesman said in a statement.
The Financial Times was the first to report the story, citing Sandy Douglas, head of a research group at Oxford. “Adenovirus-based vaccines (such as those made by Oxford/AstraZeneca) can in principle be used to counter any new mutant more quickly than some may have previously realized,” Douglas told the newspaper. And a lab study last week showed that a mixture of AstraZeneca antibodies retained neutralizing activity against the mutant Omicron. Pfizer, Biontech and Moderna have previously said they are working on vaccines targeting the Omicron mutant. Moderna said it hopes to start clinical trials early next year.
Source :Al Arabiya